Winston Francois builds pricing strategy for biotech and pharma companies where the list price you set today becomes a permanent constraint tomorrow, because Medicaid Best Price and payer expectations do not forget. We embed with your market access, finance, and legal teams instead of handing over a slide deck and disappearing.
The Problem
Formulary Access Runs Through Three PBMs You Do Not Control
Most commercial coverage in the United States funnels through CVS Caremark, Express Scripts, and OptumRx, and each one demands a rebate in exchange for favorable tier placement. Without a rebate strategy negotiated before launch, a drug lands on a disadvantaged tier behind prior authorization and step therapy, and physicians stop prescribing it before patients ever see it. That formulary status typically locks for a full plan year, so a bad opening position costs volume no field team or marketing campaign can recover in the interim.
List Price Climbs While Net Price Falls, And Finance Sees the Wrong Number
WAC increases keep showing up on schedule to protect the reported price, but rebates negotiated with payers and PBMs grow even faster underneath it, so realized net price per unit shrinks while gross revenue on paper looks stable or even up. Finance and the board build forecasts off WAC or gross bookings, then ask the commercial team to hit targets built on a price the company never actually collects. Nobody notices the gross-to-net gap widening until a quarterly close forces the conversation.
Value-Based Contracts Get Signed Before Anyone Can Measure the Outcome
Payers increasingly want rebates tied to a real-world outcome such as readmission rates or a biomarker response threshold, and market access teams agree to the structure to win the formulary slot. The problem shows up six months later when there is no data pipeline to capture the outcome, no agreed data source, and no adjudication process for a disputed result. The company is now contractually obligated to a rebate mechanism operations cannot execute.
Launch Price Gets Anchored to a Comparator Nobody Stress-Tested
Launch pricing usually gets set relative to an existing standard of care or an ICER cost-effectiveness threshold, often chosen late in the process without a clear link back to the differentiated value story the clinical and medical affairs teams actually built. Anchor too high against a familiar comparator and payers push back hard or exclude the drug from formulary entirely. Anchor too low and there is no room to raise price later, because every future negotiation starts from wherever the launch price landed.
Medicaid Best Price Turns One Discount Into a Permanent Floor
The Medicaid Best Price rule requires that the lowest price given to any commercial payer becomes the baseline used to calculate Medicaid rebate obligations nationwide, for the life of the product. A single aggressive discount offered to win one regional value-based contract can reset that floor and lock in a larger Medicaid rebate liability indefinitely, long after the original contract ends. Few teams model that exposure before signing, and by the time finance catches it, the deal is already live.
Copay Assistance Design Undermines Your Own List Price Strategy
Patient assistance and copay card programs get built to blunt out-of-pocket cost at the point of sale, but PBM copay accumulator and maximizer programs redirect that assistance so it never counts toward the patient's deductible, and the patient hits a high out-of-pocket wall anyway. On top of that, nonprofit patient assistance foundation contributions have to meet strict Anti-Kickback Statute safe harbor and Best Price exclusion requirements, or the assistance itself becomes a pricing and compliance liability. Marketing and market access rarely coordinate on this until a program is already live and generating exposure.
How We Help
We start with a two-week pricing and market access audit that maps what is actually happening, not what the strategy deck says.
From the audit we build a pricing architecture that connects every launch or reprice decision back to an actual payer value proposition, instead of an arbitrary anchor chosen late in the process.
Where a payer wants an outcomes-based structure, we build the actual measurement and adjudication process before anyone signs anything.
Before any contract gets signed, we model how it resets your Best Price floor.
On the patient-facing side, we redesign copay support architecture to survive accumulator and maximizer programs instead of getting silently neutralized by them.
We work embedded and fractional, not project-and-disappear.
What we deliver
- Pricing and market access audit covering list price history, rebate rates, net price trend, and formulary status
- Gross-to-net bridge model built for multi-year forecasting, not a single launch-year snapshot
- Payer and PBM rebate strategy scenarios tied to specific formulary tier goals
- Outcomes-based contract measurement and adjudication design, built before terms are finalized
- Medicaid Best Price exposure model run against every proposed discount or value-based contract
- Copay assistance and patient support program redesign built to survive accumulator and maximizer adjudication
- Net price and rebate liability dashboard with documented data lineage for finance and the board
The list price you set at launch is not a marketing decision, it is a permanent constraint on every future payer negotiation, because Medicaid Best Price treats your lowest real transaction as the floor for the life of the product.
Our Methodology
We run in 90-day sprints because pricing and market access decisions need to be grounded in current payer behavior, not a strategy built on data that is already a year stale. Days 1-15 are the audit: list price history, rebate rates by payer, formulary status, and current Best Price exposure calculation, if one exists. Days 16-45 are model-building: the gross-to-net bridge, rebate scenarios, and Best Price simulation get built and stress-tested against the specific contracts on the table right now. Days 46-75 are negotiation support, where we sit in on payer and PBM conversations and pressure-test proposed terms before they get signed. Days 76-90 are handoff: documented models, a dashboard finance can actually read, and a process for evaluating the next contract without starting from scratch.
This is different from a traditional pricing consultancy in one specific way: we do not hand over a recommended price point and leave. A number without the negotiation infrastructure behind it is close to useless in a market where three PBMs control most of the access. We stay embedded through the actual payer conversations, because that is where a pricing strategy either holds up or falls apart.
How We Work
The first 30 days are diagnostic. We sit down with market access, finance, and legal to get the real picture of current pricing – list price history, active rebate agreements, formulary status by payer, and whatever Best Price tracking already exists – and come back with a prioritized negotiation and modeling plan, not a slide deck nobody opens again.
Days 31-60 are model-building and negotiation prep. We are inside your systems building the gross-to-net bridge and Best Price simulation alongside your existing finance and market access staff, not handing off a spreadsheet template and waiting for questions. Weekly working sessions replace status calls, because a status call does not catch a Best Price exposure problem before a contract is signed.
By day 90 you have working models and a negotiation position, not a recommendation memo. From there we typically stay on fractional, cadence set by what is active – weekly during a live payer negotiation or launch window, biweekly once contracts are signed and the focus shifts to monitoring net price and rebate liability over time. You get direct access to the people who built the models, not an account manager relaying questions.
If your biotech or pharma company is facing a launch pricing decision, a PBM renegotiation, or a Best Price exposure question you have not modeled yet, we should talk.
- Formulary tier placement aligned with the rebate strategy negotiated in advance
- Net price realization tracked against forecast instead of discovered at quarterly close
- Value-based contracts built with a measurement process operations can actually run
- Medicaid Best Price exposure modeled before a discount or contract is signed
- Copay assistance programs that hold up against accumulator and maximizer adjudication
- One documented pricing and rebate model finance, legal, and market access all work from
If your biotech & pharma company needs pricing strategy leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How does Winston Francois help with PBM formulary negotiations?
We build the rebate strategy and financial model before you sit down with CVS Caremark, Express Scripts, or OptumRx, so the offer you bring reflects what tier placement is actually worth to your commercial forecast. We also sit in on the negotiation itself when useful, because a model that only lives in a spreadsheet does not help much in the room.
What does a pricing strategy engagement cost for a biotech or pharma company?
Engagements are scoped fractional, typically in the range of $15K-$35K per month depending on how many active payer contracts and how much modeling work is involved. That covers an embedded team, not a fixed deliverable list, because the highest-value work often shows up mid-negotiation, not at the start.
How do you model Medicaid Best Price exposure before we sign a value-based contract?
We simulate how a proposed discount or outcomes-based rebate would reset your Best Price floor across your full Medicaid book, not just the one payer in front of you. Where a legitimate exclusion applies – a bona fide service fee or a nominal price arrangement, for example – we structure the contract to use it, instead of finding out about the exposure after the deal is live.
How long before we see impact on net price realization?
The gross-to-net model and rebate scenarios are typically ready inside the first 45 days, which is when you start negotiating from a real number instead of a guess. Actual net price improvement depends on payer contract cycles, since most formulary agreements only renegotiate on an annual basis, so the financial impact often lands over the following one to two quarters.
How does your team integrate with our market access, finance, and legal teams?
We embed directly with whoever owns the relevant piece – market access on formulary and rebate strategy, finance on the gross-to-net model, legal and compliance on Best Price and Anti-Kickback Statute questions. Everyone works off the same model instead of three separate versions of the pricing picture.
What makes Winston Francois different from a traditional market access consulting firm?
A traditional market access firm typically hands over a pricing recommendation and a slide deck, then leaves before the first PBM counter-offer arrives. We stay embedded through the actual negotiation and the model handoff, because a pricing strategy that only exists on paper does not survive contact with a real payer conversation.
Is Winston Francois a good fit for a company that has not launched a product yet?
Yes, and it is often the best time to bring us in, because launch pricing decisions are the hardest ones to undo later. Building the comparator analysis, the gross-to-net model, and the Best Price simulation before launch means the first price you set is one you can actually live with, instead of one you spend the next three years trying to unwind.
